An interventional study of FibroScan in NAFLD, Type 1 Diabetes and Fatty Liver, Nonalcoholic, sponsored by Ziekenhuis Oost-Limburg. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-28.
Sponsored by Ziekenhuis Oost-Limburg · Not applicable, Interventional, and Diagnostic
To determine the prevalence of NAFLD in T1DM patients.
1,474 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 303 are open to participants now.
This study's planned enrollment of 138 is above the median of 60 across 1,072 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Browse Non-alcoholic Fatty Liver Disease studies →Ziekenhuis Oost-Limburg is the lead sponsor of 66 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
FibroScan measurement
Diagnostic Test: FibroScan
Performance of a FibroScan measurement to determine steatosis and fibrosis.
Prevalence of NAFLD in T1DM
To determine the prevalence of steatosis in a cohort of T1DM patients followed at the Departments of Endocrinology in ZOL by means of the FibroScan® device with controlled attenuation parameter (CAP) measurements.
Time frame: During the intervention
Prevalence of fibrosis in T1DM
To determine the prevalence of fibrosis in a cohort of T1DM patients followed at the Departments of Endocrinology in ZOL by means of the FibroScan® device with vibration controlled attenuation parameter (VCTE) measurements.
Time frame: During the intervention
Plan to share: No — During the study period IPD will not be made available for other researchers. When the study is completed and results are reported, IPD can be shared.
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Non-alcoholic Fatty Liver Disease→
Ziekenhuis Oost-Limburg